Defense Dept awards $138.5 M to MediVector

Privacy Policy

Privacy Policy for flucrazy.blogspot.com

The privacy of our visitors to flucrazy.blogspot.com is important to us. 

We recognize that privacy of your personal information is important. Here is information on what types of personal information we receive and collect when you use and visit and how we safeguard your information.  We never sell your personal information to third parties.

Log Files
As with most other websites, we collect and use the data contained in log files.  The information in the log files include  your IP (internet protocol) address, your ISP (internet service provider, such as AOL or Shaw Cable), the browser you used to visit our site (such as Internet Explorer or Firefox), the time you visited our site and which pages you visited throughout our site. 

Cookies and Web Beacons
We do not use cookies to store information, such as your personal preferences when you visit our site. 

We use third party advertisements on flucrazy.blogspot.com to support our site.  Some of these advertisers may use technology such as cookies and web beacons when they advertise on our site, which will also send these advertisers (such as Google through the Google AdSense program) information including your IP address, your ISP , the browser you used to visit our site, and in some cases, whether you have Flash installed.  This is generally used for geotargeting purposes (showing New York real estate ads to someone in New York, for example) or showing certain ads based on specific sites visited (such as showing cooking ads to someone who frequents cooking sites).

You can chose to disable or selectively turn off our cookies or third-party cookies in your browser settings, or by managing preferences in programs such as Norton Internet Security.  However, this can affect how you are able to interact with our site as well as other websites.  This could include the inability to login to services or programs, such as logging into forums or accounts.

The US military has awarded a $ 138.5 million dollar contract to a drug development company to develop a therapeutic for influenza.

The U.S. Department of Defense (DEFENSE THREAT REDUCATION AGENCY) awarded the contract to Mass-based MediVector, Inc  ( http://medivector.com/).

The treatment is still in the experimental phase, but has shown effectiveness in tests on rodents.

MediVector in the news:

MILITARY-INDUSTRIAL COMPLEX IN ACTION: March 12, 2012 Defense Dept. Contracts

http://www.huntingtonnews.net/26126

Aethlon Medical (AEMD) granted FDA approval to export Hemopurifier to India

Aethlon Medical, Inc. (AEMD) announced today that it has been granted FDA approval to export its Hemopurifier medical device to India.

Although not yet approved for sale in the US, the therapeutic filtration device was granted approval under section 801 (e) of the Federal Food, Drug, and Cosmetic Act for devices that are manufactured under the FDA's Good Manufacturing Practices.

According to the announcement, "Aethlon is currently conducting a clinical study entitled: "Use of the Aethlon Hemopurifier® in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy" at the Medicity Institute (Medicity) near Delhi, India. The Medicity is a $360 million multi-specialty medical institute recently established on a 43-acre campus to be a premier center of medical tourism in India. A clinical goal of the Aethlon-Medicity study will be to demonstrate that the Hemopurifier® is able to accelerate the benefit of HCV standard of care (SOC) drug regimens. Therapeutic filtration at the outset of SOC improves early virus reduction kinetics to levels associated with that of patients most likely to achieve a sustained viral response, which is the goal of HCV therapy. Additionally, lower quantities of HCV in circulation at the outset of SOC correlate with increased cure rates. Upon demonstration of treatment efficacy, Aethlon plans to commence commercialization of its Hemopurifier® in India."

Full report is here:
http://www.prnewswire.com/news-releases/aethlon-medical-receives-fda-approval-to-export-its-hemopurifier-to-india-117574578.html

Excerpt:

"Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats."